European Commission Approves Novo Holdings’ $16.5B Acquisition of Catalent
Approval:
The European Commission has granted unconditional approval for Novo Holdings' acquisition of Catalent, a global contract development and manufacturing organization12.
Transaction Value:
The acquisition is valued at $16.5 billion34.
Expected Closure:
The transaction is expected to close towards the end of calendar year 2024, subject to the satisfaction of other customary closing conditions, including receipt of all requisite regulatory clearances12.
Regulatory Progress:
The acquisition has been approved by the authorities in several jurisdictions, and Catalent stockholders voted to approve the pending transaction on May 29, 20242.
Novo Holdings' Role:
Novo Holdings is a global life sciences investment firm that manages the assets and wealth of the Novo Nordisk Foundation, aiming to improve people’s health and the sustainability of society and the planet1.
Catalent's Future:
The acquisition is expected to support Catalent in its next chapter, continuing to create value for stakeholders and delivering better outcomes for customers and patients1.
Sources:
1. https://www.catalent.com/catalent-news/catalent-and-novo-holdings-receive-european-commission-unconditional-approval-for-pending-transaction/
2. https://www.globenewswire.com/news-release/2024/12/06/2993201/0/en/The-European-Commission-approves-the-acquisition-of-Catalent-by-Novo-Holdings-and-the-related-acquisition-by-Novo-Nordisk-of-three-manufacturing-sites-from-Novo-Holdings.html
3. https://www.fiercepharma.com/pharma/sen-warren-sets-sights-novo-holdings-proposed-165b-catalent-acquisition-deal-nears